1 ORIGINAL RESEARCH

2 Mike Du et al

3 Random effects modelling vs logistic regression for the inclusion of

4 cluster level covariates in propensity scores for medical device and

5 surgical epidemiology

Author name: Mike Du¹⁺, Albert Prats-Uribe¹⁺, Sara Khalid¹, Daniel Prieto-Alhambra¹, Victoria Y Strauss^{1^}, Sara
 Khalid^{1^}

8 Author affiliations

- ¹ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre,
 Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK
- 11 ⁺These authors contributed equally to this work.
- 12 [^]Joint senior authors
- 13 Correspondence: Daniel Prieto-Alhambra
- 14 Botnar Research Centre, Windmill Road, OX3 7LD, Oxford, UK.
- 15 E-mail: daniel.prietoalhambra@ndorms.ox.ac.uk
- 16 Abstract

17 Purpose

- 18 Surgeon and hospital related features such as surgeries volume can be associated with treatment
- 19 choices and treatment outcomes. Accounting for these covariates with propensity score (PS) analysis
- 20 can be challenging due to clustered nature of the data. Previous studies have not focused solely on
- 21 the PS estimation strategy when treatment effects are estimated using random effects model(REM).
- 22 We studied PS estimation for clustered data using REM compared with logistic regression.

23 Methods

24 Six different PS estimation strategies were tested using simulations with variable cluster-level

confounding intensity (odds ratio(OR)=1.01 to OR=2.5): i) logistic regression PS excluding cluster-

- 26 level confounders; ii) logistic regression PS including cluster-level confounders; iii) same as ii) but
- 27 including cross-level interactions; iv), v) and vi), similar to i), ii) and iii) respectively but using REM
- 28 instead of logistic regression PS. Same analysis were tested in a randomised controlled trial
- 29 emulation of partial vs total knee replacement surgery. Simulation metrics included bias and mean
- 30 square error (MSE). For trial emulation, we compared observational vs trial-based treatment effect
- 31 estimates.

32 Results

- 33 In most simulated scenarios, logistic regression including cluster-level confounders gave more
- 34 accurate estimates with the lowest bias and MSE. E.g. with 50 clusters x 200 individuals and
- 35 confounding intensity OR=1.5, the relative bias= 10% and MSE= 0.003 for (i), compared to 21% and,
- 36 0.010 for (iv). In the Trial emulation, all 6 PS strategies gave similar treatment effect estimates.

37 Conclusions

- 38 Logistic regression including patient and surgeon/hospital-level confounders appears to be the
- 39 preferred strategy for PS estimation. Further investigation with more complex clustered structure is
- 40 suggested.

41 Keywords:

- 42 propensity score, simulation, trial emulation, clustered data, random effects model, causal inference
- 43

44 **Competing interests**:

- 45 Prof. Prieto-Alhambra's research group has received grant support from Amgen, Chesi-Taylor,
- 46 Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from
- 47 Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker
- 48 services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF
- 49 consortiums, and Synapse Management Partners have supported training programs organised by
- 50 DPA's department and open for external participants organized by his department outside
- 51 submitted work.
- 52

53 Ethics Approval and Informed Consent

- 54 This study was approved by the secretary of state, having considered the recommendation from the
- 55 Confidentiality Advisory Group (CAG reference: 17/CAG/0174). Informed ethical approval was given
- 56 on the use of pseudonymised patients data included in the study.
- 57 58 59 60 61 62 63 64
- 65

66 INTRODUCTION

67	Observational studies using routinely collected patient data from health registries are often used for
68	clinical treatment comparative study when randomised control trials are unfeasible or unethical(1).
69	Conversely to randomisation in trials, treatment allocation in observational data is often driven by
70	patient and physician features, leading to confounding by indication. First proposed by Rosenbaum
71	and Rubin(2, 3), propensity score (PS) weighting are a popular method to minimise the resulting
72	bias. Most PS applications in pharmacoepidemiology include only patient covariates. Conversely,
73	medical device and surgical studies typically have a clustered structure that accommodates hospital
74	and physician/surgeon features that could impact treatment and outcome and hence act as
75	confounders(4, 5).
76	Several simulation studies have shown that using random effects models(6) in the PS estimation or
77	treatment outcome modelling can reduce the bias arising from cluster level confounding in clustered
78	data(7-12). However, it is unclear whether random effects models should be used for both PS
79	estimation and outcome modelling in observational studies of medical devices or surgical
80	procedures. Therefore, this study aims to evaluate to what extent random effects model should be
81	used for PS estimation when random effects model is used to estimate the treatment outcome. This
82	study aimed to assess to what extent random effects model should be used for clustered
83	observation studies of medical device and surgical epidemiology.
84	We used Monte Carlo simulations(13), and a surgical trial emulation study comparing partial and
85	total knee replacement surgery to evaluate the accuracy and precision of random effects model

86 compared to logistic regression propensity score model.

87

88

90 METHODS

91 Simulation data generation process

92	The simulation settings were based on previous simulation studies(7, 8) but with parameters
93	adapted to medical device/surgical epidemiology data. We simulated clustered datasets via Monte
94	Carlo simulations with a fixed sample size of 10,000 individuals to represent the patients, binary
95	treatment allocation (T) and binary outcome (Y). The complete mathematical formulae for data
96	generation are included in the supplementary material. We simulated six individuals-level covariates
97	(x1 to x6), two cluster-level covariates (z1 and z2 to represent the hospital/surgeon level covariates)
98	and a cross-level interaction term between the individual and cluster-level confounder for each
99	individual. Among the individual covariates simulated, 5 were confounders (x1- x5), 1 was a risk
100	factor associated with outcome but not with exposure (x7), and 1 was an instrumental variable (x6).
101	Both cluster level covariates (z1 and z2) were generated as confounders. Figure 1 gives the clustered
102	causal diagram of the simulation covariates.
103	12 different scenarios with 1000 replications under each scenario were simulated to test: 1) three
104	different ratios of cluster: individual size: 10: 1000, 50: 200, and 500: 20; 2) different effect size for
105	z1 and z2 on outcome, ranging from negligible with odds ratio = 1.01 (resembling an instrumental
106	variable) to strong with odds ratio = 2.5 (equivalent to strong multilevel confounding). Table 1 gives
107	the generation distribution, effects on treatment allocation and effects on treatment outcome for all
108	the covariates generated in the simulations.
109	The simulation data were generated with simstudy (version 0.2.1) R package, and the propensity

score models were fitted with lme4 (version 1.1.21) R package.

111

113Figure 1: This diagram gives the causal relationship between the covariates in the simulation data, the arrow indicates114causes. For example, x1-> Y implies x1 causes Y.



Table 1: The table gives the generation distribution, effects on treatment allocation and effects on treatment outcome for
 covariates generated in the simulations. OR = odd ratio

Covariates	Description	Effects on treatment allocation (beta value)	Effects on treatment outcome (Beta value)	Generation distribution
z1,z2	Cluster-level confounders	z1 = z2 = 0.4055 (equivalent to OR=1.5)	z1 = z2 = [0.01,0.2231,0.4055,0.9163] ~ [equivalent to OR =1.01,1.25,1.5,2.5]	z1 ~ N(0,1), z2 ~ Bernoulli(0.5)
x1 to x5	Individual level confounders	[x1,x2,x3,x4,x5] = [0.35,0.4,0.45,0.5,0.55]	[x1,x2,x3,x4,x5] = [0.35,0.4,0.45,0.5,0.55]	[x1,x2,x3]~Bernoulli ([0.4,0.45,0.5]) x4,x5 ~ N(0,1)
х6	Individual level risk factor	0	0.5	Bernoulli(0.5)
x7	Individual level instrumental variable	0.5	0	Bernoulli(0.5)
z1*x1	Cross level interaction term	0.4055 (OR =1.5)	0	z1*x1

131 **Propensity score estimation strategy**

- 132 For all the data scenario described in the simulation data generation process, we tested six different
- 133 strategies to incorporate propensity score, as defined in Table 2.
- 134Table 2: The table gives the cluster level information contained and the statistical models used for the six propensity score135estimation strategies (M1 to M6).

Propensity score strategy	Cluster level confounders as covariates in PS model	Cross level confounders interaction term as covariate in PS model	Statistical model to build a propensity score
M1	Excluded	Excluded	Logistic regression
M2	Included	Excluded	Logistic regression
M3	Included	Included	Logistic regression
M4	Excluded	Excluded	Random effects model ¹
M5	Included	Excluded	Random effects model ¹
M6	Included	Included	Random effects model ¹

136 1 The random effects model were built with logit link function

137

138

140 Treatment effect estimation

- 141 For each of the scenarios, the average treatment effect (ATE) was estimated using random effects
- 142 models with logit function regress on treatment outcome weighted with stabilised inverse
- 143 probability weighting (SIPW)(14) based on propensity scores calculated using the strategies
- described in table 2. Random effects model was use for treatment effect estimation since several
- simulation studies on propensity score(7, 8) have shown that using random effects models to
- account for the cluster level confounding generally gives the least bias.

147 Assessment of simulation results

- 148 We measured each propensity score specification strategy's performance on each scenario by
- 149 calculating the 1) absolute relative bias (%), defined as the average percentage difference between
- 150 the true treatment effect and the estimated treatment effect. 2) mean square error (MSE), which is
- a measure of accuracy. 3) 95% confidence interval model coverage, defined as the proportion of the
- 152 95% confidence intervals of the estimated treatment effect effects containing the true treatment
- 153 effect. All the performance measures were calculated following the simulation study guidelines
- discussed in Morris et al(15) with "rsimsum" (version 0.9.1) R package.

155 Case study on medical device and surgical epidemiology

- 156 We used data from the UTMOST study(16), which aimed to identify the optimal methods for
- 157 controlling confounding when emulating the results of the TOPKAT surgical trial(17). The UTMOST
- 158 cohort study included patients with a first primary total knee replacement (TKR) or
- unicompartmental knee replacement (UKR)(18) in the UK National Joint Registry (NJR) from 2009 to
- 160 2016 who would have met the TOPKAT trial eligibility criteria. UTMOST included a total of 294556
- patients (294556 UKR and 21,026 TKR patients), and 6420 different lead surgeons carried out the
- 162 interventions. UTMOST extracted 18 patient-level covariates from the NJR, linked to Hospital
- 163 Episode Statistics (HES) records and patient-reported outcome measures, and the volume of UKR

164 performed by each lead surgeon in the previous year from the NJR. The UTMOST study outcor

- revision five years after surgery. Table 3 gives the covariates adjusted in the study.
- 166 We applied the six proposed propensity score specification strategies from table 2 to the UTMOST
- 167 dataset to construct the propensity scores for UKR and compared it to the results of the TOPKAT
- surgical trial. The cross-level interaction term considered in UTMOST was the interaction of surgeon
- volume and patient gender. As with the simulated data described in the method section, we
- 170 modelled the 5-year revision risk for patients received UKR using a random effects model with the
- 171 lead surgeon as cluster level while covariates were adjusted with stabilised inverse probability
- 172 weights.
- 173
- 174
- 175
- 176
- 177
- 178

179

- 180
- 181
- 182

183

185 Ta	able 3:: This table gives the o	ovariates adjusted in th	e case study. UKR = u	nicompartmental knee	replacement NJR =
--------	---------------------------------	--------------------------	-----------------------	----------------------	-------------------

186 National Joint Registry. 1 standardised measure of health-related quality of life developed by the EuroQol Group

Covariates	Type/description
Socio-demographic covariates	Patient covariates (individual level)
Age	Continuous covariate
Gender	Binary covariate
Rural Urban	Categorical covariate – urban/town and fringe/village/isolated
IMD	categorical covariate in 10 percentiles from least deprived to most deprived
BMI	Continuous covariate
Pre-Operative Patient Reported Outcomes	Patient covariates (individual level)
pre-operative OKS	Continuous covariate
EQ-5D ¹	Continuous
General health	Categorical covariate with discrete scale excellent/1/2/3/4/poor
Comorbidities 3-year before surgery	Patient covariates (individual level)
Charlson comorbidity	Binary covariate
Gastrointestinal disease	Binary covariate
Osteoarthritis and other joint problems	Binary covariate
Mental health	Binary covariate
Respiratory disease	Binary covariate
Cardiovascular disease	Binary covariate
Thyroid problems	Binary covariate
Foot, hip, spinal pain	
Foot, hip, spinal pain	Binary covariate
Coxarthrosis	Binary covariate
Neurological disorders	Binary covariate
Other arthrosis	Binary covariate

	Polyarthrosis	Binary covariate
	Spondylosis	Binary covariate
	Surgeon's feature covariates	Surgeon covariates (cluster level)
	Surgery volume of UKR performed by each lead surgeon in the previous year from the NJR	Continuous covariate
187		
188		
189		
190		
191		
192		
193		
194		
195		
196		
197		
198		
199		
200		
201		
202		

203 **RESULTS**

204 Simulation study

205	Figures 3 and 4 gav	e the simulations average	absolute relative	bias and MSE o	of the treatment effect
-----	---------------------	---------------------------	-------------------	----------------	-------------------------

- 206 estimates for propensity score estimation strategy M1 to M6. There were few clear trends appeared
- 207 from figure 3 and 4 that were consistent in all cluster structure scenario. The relative bias and MSE
- 208 for models with and without the cross-level interaction were similar, for example, relative bias =

209 9.42% in M2 and relative bias = 9.53% in M3 for cluster level confounders odd ratio (OR) = 1.01,

- cluster structure (10,1000) scenario, suggesting that not incorporating the cross-level correlation
- 211 where there is one did not impact on bias much. In scenarios where the cluster level confounders
- had minimal effect on outcome (OR = 1.01), the model where propensity score without cluster level
- 213 confounders in the logistic regression (M1) gave the lowest bias when compared to other PS models.
- 214 By contrast, M1 did not always gave lowest relative bias and MSE when the effect size of cluster
- 215 level confounders OR were greater than 1.01.

216 For cluster structure with small cluster number and large cluster size (m = 10, n = 1000) and (m = 50, 217 n =200) using random effects model for propensity score estimation (M4, M5, M6) consistently gave 218 higher bias compared to using logistic regression model (M1, M2, M3). For example, the relative bias 219 for M4 is 21.1% compared to 9.53% for M1 in cluster structure (m = 50, n = 200) and cluster level 220 confounders effect size odd ratio 1.5 scenario. Also, adding the cluster level confounders as 221 covariates in the propensity score model did not impact the bias much in cluster number (m), cluster 222 size (n) = [(10, 1000), (50, 200)] scenarios regardless of the cluster level confounder effect size on the 223 treatment outcome. Since the relative bias for M1 compared to M2 and M3, and the relative bias 224 M4 compared to M5 and M6 are very similar.

The results for the smallest cluster size scenarios (m = 200, n = 50) behaved differently compared to the other two cluster structures tested in the study. Apart from in the cluster confounder effect on

227	outcome OR = 1.01 scenario. The relative bias for propensity score strategy that either included the
228	cluster level confounders as covariates in the propensity score model or used a random effects
229	model to account for the cluster structure of the data (M2 to M6) reduced bias compared to
230	propensity score strategy did not consider the cluster level (M1). The improvement in bias and MSE
231	was greater as the cluster level confounders effect on outcome increases. For example, the relative
232	bias for M1 = 14.02% compared to M2 = 9.48% for cluster level confounders effect on outcome OR =
233	1.5. For cluster level confounders effect size on outcome OR = 2.5, the relative bias for M1 = 20.16%
234	compared to M2 = 10.54%.
235	
236	
237	
238	
220	
239	
240	
241	
242	
242	
243	
244	
245	
245	
246	
247	

Figure 2: The graphs give the simulation treatment effects average absolute relative bias and 95% confidence interval for propensity score specification strategies M1 to M6 for different cluster structure and cluster (surgeon) level confounder odd ratio on treatment outcome. Structure = (number of clusters, individuals per cluster), surgeon OR = cluster level confounder odd ratio on treatment outcome. Propensity score(PS) strategies: M1 = logistic regression PS excluding cluster-level confounders; M2 = logistic regression PS including cluster-level confounders, M3 = logistic regression PS with cluster level confounders and cross level interaction term, M4 = random effects PS excluding cluster-level confounders, M5 = random effects PS including cluster-level confounders, M6 = random effects PS with cluster level confounders and cross level interaction term







Figure 3: The graphs give the simulation treatment effects average mean square error and 95% confidence interval for
 propensity score specification strategies M1 to M6 for different cluster structure and cluster (surgeon) level confounder odd
 ratio on treatment outcome. Structure = (number of clusters, individuals per cluster), surgeon OR = cluster level confounder
 odd ratio on treatment outcome. Propensity score(PS) strategies: M1 = logistic regression PS excluding cluster-level
 confounders; M2 = logistic regression PS including cluster-level confounders, M3 = logistic regression PS with cluster level
 confounders and cross level interaction term, M4 = random effects PS excluding cluster-level confounders, M5 = random
 effects PS including cluster-level confounders, M6 = random effects PS with cluster level confounders and cross level

271 interaction term



Figure 4 gave the 95% CI model coverage for the simulation study. It showed that low coverage was
a major issue for treatment effects estimates using random effect model based propensity score
model (M4 to M6) when the cluster size was large (n = 1000 and n = 200) as the model coverage for
M4 M5 M6 were much lower than M1 M2 M3. In our small cluster size scenario (n = 20), the model
coverage between M4 M5 M6 and M1 M2 M3 were more closely matched. However M2 and M3 still
gave higher model coverage then M4 M5 M6.

279 Figure 4: The graphs give the simulation treatment effects average 95%CI model coverage probability and its 95%

280 confidence interval for propensity score specification strategies M1 to M6 for different cluster structure and cluster level

281 confounder odd ratio on treatment outcome. Structure = (number of clusters, individuals per cluster), surgeon OR = cluster

282 level confounder odd ratio on treatment outcome. Propensity score(PS) strategies: M1 = logistic regression PS excluding
 283 cluster-level confounders; M2 = logistic regression PS including cluster-level confounders, M3 = logistic regression PS with

cluster-level confounders; M2 = logistic regression PS including cluster-level confounders, M3 = logistic regression PS with
 cluster level confounders and cross level interaction term, M4 = random effects PS excluding cluster-level confounders, M5 =

285 random effects PS including cluster-level confounders, M6 = random effects PS with cluster level confounders and cross level

286 *interaction term . The black vertical dotted line indicates 95%.*



287

288

289

290

292 Real world case study

299

293 Figure 5:Treatment effects estimates in relative risk and its 95% confidence interval using data from the UTMOST study and 294 the six proposed propensity score strategies M1 To M6 and also the TOPKAT surgical trial estimates. TOPKAT = surgical trial 295 estimates. Propensity score(PS) strategies: M1 = logistic regression PS excluding cluster-level confounders; M2 = logistic 296 regression PS including cluster-level confounders, M3 = logistic regression PS with cluster level confounders and cross level

297 interaction term, M4 = random effects PS excluding cluster-level confounders, M5 = random effects PS including cluster-298





300 Figure 5 gives the treatment effect estimates using the six propensity score strategies (M1 to M6) 301 proposed for the case study (UTMOST) and the TOPKAT surgical trial estimates. We found that 302 under all model strategies, UKR had a higher risk for 5-year revision than TKR. In contrast, TOPKAT 303 found no statistically significant difference in the revision risk between UKR and TKR. Models that 304 incorporated multilevel data or not or/and included the cluster-level confounders in the propensity 305 score model had an overlapping confidence interval of outcome estimates. This meant all six 306 proposed propensity score strategies (M1 to M6) gave similar treatment estimates and were not 307 statistically significantly different. In addition, propensity score models with and without cross level

- 308 interaction term had similar estimates (M2 vs M3, M5 vs M6), suggesting that adding the cross level
- 309 interaction term in the propensity score models did not impact the estimate.

327 CONCLUSION AND DISCUSSION

328 Discussion

329	This study aimed to find the best way to account for cluster level confounding in propensity score
330	model for propensity score weighting analysis when random effects model was used to estimate the
331	treatment outcome. In our simulation study, we found accounting for the cluster level confounders
332	in the propensity score model when random effects model was used as the outcome model does not
333	always give the smallest bias. For cluster structures with small cluster number and large cluster size
334	(m = 10, n = 1000) and (m =50, n =200), strategy that ignored the cluster level confounders (M1)
335	performed the best. Including the cluster level confounders in the propensity score model by using
336	random effects model and as covariates in the model only offered improvement in bias for small
337	cluster size scenarios (m = 500, n = 20). This is consistent with previous studies on propensity score
338	for clustered data(7, 8, 12), which shows random effects model might give more accurate estimation
339	in propensity score compared to logistics regression but not necessary improvement in accuracy for
340	treatment estimation. However in our simulation study we also showed the optimal propensity
341	score model strategy were dependent on clustered structure and cluster level confounder effect on
342	outcome. Whereas previous simulations study(8, 12) on this topic were more focus on the
343	performance of different weighting approaches. We also found that adding the cross-level
344	interaction term made little impact to the treatment effect in the simulation study.
3/15	Applying the proposed propensity score strategies to real-world clinical study corroborated with
545	Appring the proposed propensity score strategies to real-world childer study corroborated with
346	some but not all our simulation results. Including a cross-level interaction term in either the logistic
347	regression or random effects model did not substantially change the estimated treatment effect,
348	same as the simulation study result. However, the treatment effect estimates in the real-world
349	clinical study all had overlapping confidence intervals, meaning all six propensity score strategies
350	(M1 to M6) gave similar results, different from our simulation results. There were few differences
351	between the cluster structure, which could contribute to these differences in the result. First, the

cluster size was fixed in the simulation study, but the cluster size was varied for the real-world
clinical study. Second, we found that many surgeons only carried out one type of treatment in the
real-world clinical study. However, in our simulation study, the treatment is allocated individually,
meaning both treatments can appear in all clusters. This discrepancy of results between our realworld clinical study and simulation also highlighted that the cluster structure of the data affects the
accuracy and precision of results for propensity score weighting analysis. More research is needed
on how different cluster structures affect propensity score weighting analysis.

359 Strengths and Limitation of the study

360 This study's main strength is its use of both simulations and real-world data. Using simulated data,

361 where the true average treatment effect was known, allowed us to compare the accuracy of the six

362 proposed PS estimation strategies. Using clinical data allowed us to test whether the trends from the

363 simulation study were held with real-world data.

364 This study has several limitations. In the simulation study, we investigated only fixed cluster number 365 and size scenarios in the scenarios. Our real-world case study found the simulation findings may not 366 be able to generalise to the scenario when cluster number and size was not fixed. In addition, we 367 only tested the propensity score strategies on binary outcomes. Therefore, our results cannot 368 generalise to other types of outcomes. We also assumed that the treatment assignment was only 369 influenced by a small set of covariates in the simulation study. It could be argued that in real world 370 settings, the data would usually contain more covariates. However, the focus of this study was not 371 on covariates number. Finally, the TOPKAT trial treatment estimate was underpowered in the real-372 world case study. As a result, the 95% confidence interval for the trial treatment estimate was large, 373 making it difficult to compare the accuracy of the treatment effects from the UTMOST data.

374

376 Conclusion

377 In summary, careful consideration of the cluster structure is ne	ecessary to decide on whether to use a.
--	---

- 378 random effects model on propensity score estimation. We should only consider using random
- 379 effects model for propensity score model when the dataset contains large numbers of small clusters.
- 380 Also, we should consider including cluster level confounders as covariates in the propensity score
- 381 model when the cluster level confounders are thought to strongly affect the treatment outcome, as
- this can reduce bias.

396 **REFERENCES**

Bernard A, Vaneau M, Fournel I, Galmiche H, Nony P, Dubernard JM. Methodological choices
 for the clinical development of medical devices. Med Devices (Auckl). 2014;7:325-34.

ROSENBAUM PR, RUBIN DB. The central role of the propensity score in observational studies
 for causal effects. Biometrika. 1983;70(1):41-55.

4013.Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using Subclassification on402the Propensity Score. Journal of the American Statistical Association. 1984;79(387):516-24.

403 4. Papachristofi O, Klein AA, Mackay J, Nashef S, Fletcher N, Sharples LD, et al. Effect of

404 individual patient risk, centre, surgeon and anaesthetist on length of stay in hospital after cardiac

405 surgery: Association of Cardiothoracic Anaesthesia and Critical Care (ACTACC) consecutive cases

- 406 series study of 10 UK specialist centres. BMJ Open [Internet]. 2017 2017/09//; 7(9):[e016947 p.].
- 407 Available from: <u>http://europepmc.org/abstract/MED/28893748</u>
- 408 <u>https://doi.org/10.1136/bmjopen-2017-016947</u>
- 409 <u>https://europepmc.org/articles/PMC5595188</u>

410 https://europepmc.org/articles/PMC5595188?pdf=render.

- 411 5. Montgomery K, Schneller ES. Hospitals' strategies for orchestrating selection of physician
 412 preference items. Milbank Q. 2007;85(2):307-35.
- 413 6. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an 414 update. Contemporary clinical trials. 2007;28(2):105-14.
- 415 7. Arpino B, Mealli F. The specification of the propensity score in multilevel observational 416 studies. Comput Stat Data Anal. 2011;55(4):1770-80.
- 417 8. Li F, Zaslavsky AM, Landrum MB. Propensity score weighting with multilevel data. Statistics 418 in Medicine. 2013;32(19):3373-87.

4199.Schuler MS, Chu WH, Coffman D. Propensity score weighting for a continuous exposure with420multilevel data. Health Services and Outcomes Research Methodology. 2016;16(4):271-92.

- 421 10. Yang S. Propensity Score Weighting for Causal Inference with Clustered Data. J Causal
 422 Inference. 2018;6(2):19.
- 11. Cafri G, Austin PC. Propensity score methods for time-dependent cluster confounding. Biom
 J. 2020;62(6):1443-62.
- Fuentes A, Lüdtke O, Robitzsch A. Causal Inference with Multilevel Data: A Comparison of
 Different Propensity Score Weighting Approaches. Multivariate Behavioral Research. 2021:1-24.
- 427 13. Raychaudhuri S, editor Introduction to Monte Carlo simulation. 2008 Winter Simulation
 428 Conference; 2008 7-10 Dec. 2008.
- 429 14. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse
 430 propensity scores as weights to directly estimate relative risk and its confidence intervals. Value
 431 Health. 2010;13(2):273-7.

432 15. Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods.
433 Statistics in Medicine. 2019;38(11):2074-102.

Prats-Uribe A, Kolovos S, Berencsi K, Carr A, Judge A, Silman A, et al. Unicompartmental
compared with total knee replacement for patients with multimorbidities: a cohort study using
propensity score stratification and inverse probability weighting. Health Technol Assess.

- 430 propensity score stratific 437 2021;25(66):1-126.
- 438 17. Beard DJ, Davies LJ, Cook JA, MacLennan G, Price A, Kent S, et al. The clinical and cost-
- 439 effectiveness of total versus partial knee replacement in patients with medial compartment
- 440 osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. The Lancet.
- 441 2019;394(10200):746-56.
- 442 18. Wilson HA, Middleton R, Abram SGF, Smith S, Alvand A, Jackson WF, et al. Patient relevant 443 outcomes of unicompartmental versus total knee replacement: systematic review and meta-
- 443 outcomes of unicompartmental versus total knee replacement: systematic review and meta-
- 444 analysis. BMJ. 2019;364:l352.

445

446	Abbreviations: PS,	propensity	score; OR,	odd ratio; REM,	random effects	model; MSE, mean	square
-----	--------------------	------------	------------	-----------------	----------------	------------------	--------

- 447 error; UKR, unicompartmental knee replacement; TKR, total knee replacement; NJR, UK National
- 448 Joint Registry